ProTarget

A Danish Nationwide Clinical Trial on Targeted
Cancer Treatment Based on Genomic Profiling

 

Latest News

News from the ProTarget trial

18
Nov
How can we better predict which cancer patients will benefit from immunotherapy? This is the central question addressed in Yuliu Guo’s PhD thesis, Computational Discovery and Characterization of Multi-Source Cancer Neoepitopes for Immune Checkpoint Inhibitor...
Read More
26
Oct
On Friday 23rd of October we presented new results from two separate cohorts in ProTarget. The results were presented at the ESMO conference in Madrid, Spain, and may help refine patient selection for BRAF/MEK-inhibitors and PARP-inhibitors, respectively, beyo...
Read More
About us
The ProTarget study - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on Genomic Profiling

The ProTarget study is a Danish investigator-initiated phase 2 clinical trial that aims to facilitate patient access to commercially available molecularly targeted anti-cancer drugs based on tumor genomic profiling.

The trial aims to investigate the safety and efficacy of these treatments, when they are used outside the labeled indication to treat patients with relevant actionable targets. By doing this, we aim to identify new predictive biomarkers for targeted treatments outside the labeled indication and provide new data and essential insights in molecular pathways involved in e.g., resistance to targeted therapies.

Read more